| Continuing operations | — | — |
| Income | — | — |
| Revenue from operations | 133,217.4a | 118,130.97a |
| Other income (net) | 1,137.22a | 8,399.94a |
| Total income | 134,354.62a | 126,530.91a |
| Expenses | — | — |
| Cost of materials consumed | -30,012.72a | -31,578.22a |
| Purchases of stock-in-trade | -15,660.03a | -14,511.7a |
| Changes in inventories of work-in-process, stock-in-trade and finished goods | -2,139.33a | -1,956.22a |
| Employee benefits expense | -30,220.61a | -28,681.43a |
| Finance costs | -2,070.65a | -5,159.69a |
| Depreciation, amortisation and impairment expense | -4,860.1a | -5,819.06a |
| Other expenses | -35,949.56a | -33,362.53a |
| Total expenses | -116,634.34a | -117,156.41a |
| Profit before exceptional items and tax | 17,720.28a | 9,374.5a |
| Exceptional items - expense / (income) | 3,728.19a | 9,009.55a |
| Profit before tax from continuing operations | 13,992.09a | 364.95a |
| Tax expense | — | — |
| Current tax | -3,823.41a | -11,155.52a |
| Deferred tax | -302.74a | -7,517.93a |
| Total tax expense | -3,520.67a | -18,673.45a |
| Profit for the year from continuing operations | 10,471.42a | -18,308.5a |
| Attributable to | — | — |
| Non-controlling interest | 0.45a | 681.46a |
| Equity shareholders of Glenmark Pharmaceuticals Limited | 10,470.97a | -18,989.96a |
| Profit before tax from discontinued operations | | 5,326.92a |
| Tax expense of discontinued operations | — | — |
| Current tax | | -1,284.32a |
| Deferred tax | | -69.32a |
| Total tax expense | | -1,353.64a |
| Profit for the year from discontinued operations | | 3,973.28a |
| Attributable to | — | — |
| Non-controlling interest | | |
| Equity shareholders of Glenmark Pharmaceuticals Limited | | 3,973.28a |
| Profit/(loss) after tax for the period from continuing and discontinued operations | 10,471.42a | -14,335.22a |
| Non-controlling interest | 0.45a | 681.46a |
| Equity shareholders of Glenmark Pharmaceuticals Limited | 10,470.97a | -15,016.68a |